Extract 48 COVID RNA Samples in Just 17 Minutes with the Latest Technology from Genolution & Premas Life Science

Premas Life Sciences (PLS) and Genolution (a South Korea based company) has announced a new sales distribution agreement, appointing Premas Life Sciences as technology and knowledge distributor of Nextractor NX-48S Platform in India. Nextractor NX-48S is a fully automated Nucleic Acid Extraction system that can extract upto 48 samples in one run in 17 minutes only. These systems are currently being used extensively in COVID affected countries for Viral RNA Extraction for COVID-19 testing and in a short time we have already had 30 installations in India.

[caption id="attachment_145909" align="aligncenter" width="901"] Nextractor NX-48S Platform[/caption]

Through this partnership, Premas Life Sciences will empower Genolution's revolutionizing technology that can significantly ramp up the current efforts in #COVID19 testing, powered with Nextractor's complete automation, high throughput and reduced manual error.

Deuk Soo Na, Executive Director, Genolution commented, "We are very glad to have good and close relationship with highly esteemed Premas Life Sciences. We are pleased to serve Indian and Indian healthcare market with stunning 48-sample extraction of DNA/RNA in 17 min amid COVID-19. We expect closer cooperation with PLS in many fields in the future."

Dr. Debjani Saha, Group Product Manager, Premas Life Sciences commented, "We at Premas Life Sciences pride ourselves in bringing cutting edge technologies in the area of Genomics & Cell Biology to India and are elated to add Genolution to our ensemble menu of Products.

In the current COVID pandemic situation where we are looking for approx. 5 Lakh Viral RNA extraction per day, Nextractor's fast extraction protocol saves time and reduced manual error to get high quality RNA ready for high throughput downstream molecular analysis with RTPCR or NGS. Also, the minimal hands on time is extremely desirable while handling infectious samples."

Codex & Premas Life Sciences Partner to Launch World's 1st and Only Fully Automated Gene Synthesis Platform in India

Premas Life Sciences (PLS) and Codex (previously known as SGI-DNA) today announced a new sales distribution agreement, appointing Premas Life Sciences as the exclusive technology and knowledge distributor of Codex's BioXP 3200 Platform in India. This is the world's first fully automated system that can synthesize upto 32 genes, libraries and clones in a single overnight run.

Through this partnership, Premas Life Sciences will empower Codex's revolutionizing technology that can significantly ramp up the current efforts in #COVID19 vaccine development, powered with BioXP's complete automation, high throughput and reduced manual error.

[caption id="attachment_145459" align="aligncenter" width="1024"] BioXp™ 3200 system[/caption]

Brian Donnelly, CCO, Codex commented, "The global scientific community has made tremendous advances in reading and understanding DNA over the past 20 years. We are now in an era where the focus is on enabling scientists to translate those insights into solutions that improve lives and the sustainability of the planet. The BioXp 3200 system allows, for the first time, scientists in India to automate, speed and optimize DNA design and synthesis in the privacy of their own lab. Our technologies combine speed and security for innovators in the fields of drug discovery, vaccine development, personalized medicine, and beyond."

"India is an exceptionally important market for drug and vaccine development, and we are pleased to announce our partnership with Premas Life Sciences, a world-class sales distributor with an impeccable track record. We look forward to expanding our presence in India through this partnership and supporting the scientific community with our portfolio of synthetic biology products. Together, we are resolutely focused on empowering scientists in India with all they need to build biology so that they can change the world. Never has this been more important than right now," added Brian Donnelly.

Praveen Gupta, MD, Premas Life Sciences commented, "We at Premas Life Science pride ourselves in bringing cutting edge technologies in the area of Genomics to India and are elated to add Codex to our ensemble menu of Products. Codex brings in the world's first and only Gene printer that is BioXp 3200 which enables researchers to print their genes overnight in the comforts and privacy of their own labs. This will catalyse the Cloning process and save precious time to get the clones ready thereby democratizing gene synthesis and pushing Indian companies and academia to support 'Make In India' vision with Synthetic Biology. We believe Premas market reach combined with BioXp 3200 technical prowess will spur the Indian pursuits of synthetic biology in academics as well as industrial applications of Biopharma, Diagnostics, Biofuels and many others including the much needed vaccine production for COVID-19."